But HMAs did not prolong the RFS of AML patients with TET2 (2‐year RFS: 0 vs not reach, P = .206) or DNMT3A mutation (2‐year RFS: 66.7% vs 50.0%, P = .305), which needs to be explored further due to the small sample size of specific cohort. This evidence concerns the gene TET2 and acute myeloid leukemia.